Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1972 • 2018 ACR/ARHP Annual Meeting
Resolving the Synovial Fluid Proteome and Peptidome for Disease-Specific Mediators of Inflammatory Arthritis
Shalini Mahendran¹, Eleftherios Diamandis² and Vinod Chandran³, ¹Laboratory Medicine and Pathobiology, University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ²Pathology and Laboratory Medicine, University of Toronto, Mount Sinai Hospital, University Health Network, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Idiopathic inflammatory arthritis (IA) is a T-cell driven chronic condition characterized an imbalance in cell proliferation and apoptosis leading to significant synovial hyperplasia and…
Abstract Number: 2133 • 2018 ACR/ARHP Annual Meeting
Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Hyungjoo Kang², Yujin Park⁴ and Jeffrey Greenberg^2,5, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are 3 common inflammatory rheumatic diseases that can lead to deformities and joint destruction;…
Abstract Number: 2135 • 2018 ACR/ARHP Annual Meeting
Identification of Psoriatic Arthritis Using an Administrative Claims-Based Algorithm
Julia Ford¹, Lindsey A. MacFarlane¹, Angela Tong² and Seoyoung C. Kim^1,3, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that can present variably in patients with or without psoriasis. The ability to accurately identify PsA…
Abstract Number: 231 • 2018 ACR/ARHP Annual Meeting
Rates of Influenza Vaccination in a Cohort of Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Andreea Coca¹, James Dolan² and Christopher T. Ritchlin², ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: The infections complicating rheumatic diseases cause significant morbidity and mortality. Rheumatoid arthritis and psoriatic arthritis patients are at increased risk of infection due to…
Abstract Number: 2164 • 2018 ACR/ARHP Annual Meeting
IMPACT of a Systematic Screening of Multimorbidities in Patients with Chronic Inflammatory Rheumatic Diseases
Mégane Beurai-Weber Jr.¹, Audrey Jaussent², Guilhem du Cailar³, Marie-Christine Picot², François Roubille Sr.⁴, Jean-David Cohen⁵, Jacques Morel⁶, Jean Bousquet⁷, Pierre Fesler⁸, Bernard Combe⁹ and Claire Daien¹⁰, ¹Rheumatology Department, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ²Department of medical information, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ³Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ⁴Department of cardiology, Arnaud de Villeneuve Hospital and Montpellier University, MONTPELLIER, France, ⁵IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷MACVIA-France, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ⁸Internal medicine and hypertension, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁹University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France, ¹⁰Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France
Background/Purpose: EULAR proposes to screen multimorbidities in chronic inflammatory rheumatic diseases. The aim of the study was to assess i) multimorbidities in patients with chronic…
Abstract Number: 681 • 2018 ACR/ARHP Annual Meeting
Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor
Dan Gromer¹, Laura C. Coates², Oliver FitzGerald³, Blanca Himes⁴, Philip Helliwell⁵ and Alexis Ogdie⁶, ¹University of Pennsylvania, Medical Student, Philadelphia, PA, ²University of Oxford, Oxford, United Kingdom, ³Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁴Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁵LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that affects the skin, joints, and soft tissues. No metrics exist to indicate whether an…
Abstract Number: 2447 • 2018 ACR/ARHP Annual Meeting
Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs
Enrique R Soriano¹, Hugo Madariaga², Oswaldo Castañeda³, Gustavo Citera⁴, Emilce E Schneeberger⁴, Mario H Cardiel⁵, Thijs Hendrikx⁶, Daniela Graham⁷, Harry Shi⁶ and Dario Ponce de Leon⁸, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Clínica del Sur, Arequipa, Peru, ³Clínica Anglo Americana, Lima, Peru, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Centro de Investigación Clínica de Morelia, Morelia, Mexico, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Lima, Peru
Background/Purpose: Non-alcoholic fatty liver disease, characterized by hepatic steatosis (HS), is a very common form of chronic liver disease in many countries. Limited data are…
Abstract Number: 685 • 2018 ACR/ARHP Annual Meeting
Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
William FC Rigby¹, Gerd R. Burmester², Oliver FitzGerald³, Valderilio F Azevedo⁴, Peter Nash⁵, Thijs Hendrikx⁶, Daniela Graham⁷, Cunshan Wang⁷ and Thomas Jones⁶, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Charité – University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology, St Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College, Dublin, Ireland, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵University of Queensland, Brisbane, Australia, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In most countries where tofacitinib is…
Abstract Number: 2568 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial
Philip J. Mease¹, Arthur Kavanaugh², Andreas Reimold³, Hasan Tahir⁴, Juergen Rech⁵, Stephen Hall⁶, Piet Geusens⁷, Pellet Pascale⁸, Evie Maria Delicha⁹, Luminita Pricop¹⁰ and Shephard Mpofu⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²University of California, San Diego, School of Medicine, La Jolla, CA, ³Hospital of Southern Norway, Kristiansand, Norway, ⁴Rheumatology, Barts Health NHS Trust, London, United Kingdom, ⁵Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Monash University,, Melbourne, Australia, ⁷University of Hasselt, Belgium and Maastricht University Hospital, Maastricht, Netherlands, ⁸Novartis Pharma AG, basel, Switzerland, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab (SEC), a fully human monoclonal IgG1 antibody, provided rapid and significant improvements in all key clinical domains of psoriatic arthritis (PsA) in the…
Abstract Number: 698 • 2018 ACR/ARHP Annual Meeting
Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Michael D. George¹, Joshua Baker² and Alexis Ogdie³, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ³Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Methotrexate and TNF inhibitors (TNFi) are commonly used in the treatment of RA, PsA, and other SpA. While MTX is a mainstay of RA…
Abstract Number: 2577 • 2018 ACR/ARHP Annual Meeting
Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study
Anthony Turkiewicz¹, Amanda M. Gellett², Lisa Kerr², Julie Birt² and Jordi Gratacos³, ¹Rheumatology Associates, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN, ³Rheumatology, Hospital Parc Taulí, Sabadell - Barcelona, Spain
Background/Purpose: PsA is a chronic and complex inflammatory disease with both articular and extra-articular symptoms, including joint pain, enthesitis, dactylitis, fatigue, and skin and nail…
Abstract Number: 702 • 2018 ACR/ARHP Annual Meeting
Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Dongze Wu¹, Priscilla Wong¹, James F Griffith², Jiang Yue¹ and Lai-Shan Tam³, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ³Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Psoriatic arthritis (PsA) often leads to structural damage with resultant disability and reduced quality of life. Biologic disease modifying anti-rheumatic drugs (bDMARDs), including tumor…
Abstract Number: 2588 • 2018 ACR/ARHP Annual Meeting
Baseline Pain Severity As a Predictor of Pain Improvement Following Treatment with Tofacitinib in Psoriatic Arthritis
Alexis Ogdie¹, Kurt de Vlam², Andrew G Bushmakin³, Joseph C Cappelleri³, Philip J. Mease⁴, Roy Fleischmann⁵, Peter C. Taylor⁶, Valderilio F Azevedo⁷, Lara Fallon⁸, Anna Maniccia⁹ and John Woolcott¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²UZ Leuven, Leuven, Belgium, ³Pfizer Inc, Groton, CT, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Oxford, Oxford, United Kingdom, ⁷Universidade Federal do Paraná, Curitiba, Brazil, ⁸Pfizer Canada, Montreal, QC, Canada, ⁹Pfizer Inc, New York, NY, ¹⁰Pfizer Inc, Collegeville, PA
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA), and it is recommended that all randomized controlled trials (RCTs) in patients (pts) with PsA…
Abstract Number: 1018 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Impairs Monocyte-Derived Dendritic Cell Differentiation in Rheumatoid Arthritis and Psoriatic Arthritis.
Viviana Marzaioli¹, Mary Canavan¹, Achilleas Floudas¹, Siobhan C. Wade¹, Candice Low², Douglas J. Veale² and Ursula Fearon¹, ¹Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ²Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland
Background/Purpose: Tofacinitib (Pfizer) is an oral Janus kinase inhibitor, recently approved for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Although its mechanism…
Abstract Number: 2594 • 2018 ACR/ARHP Annual Meeting
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
Kurt de Vlam¹, Alexis Ogdie², Andrew G Bushmakin³, Joseph C Cappelleri³, Roy Fleischmann⁴, Peter C. Taylor⁵, Valderilio F Azevedo⁶, Lara Fallon⁷, Anna Maniccia⁸, John Woolcott⁹ and Philip J. Mease¹⁰, ¹UZ Leuven, Leuven, Belgium, ²University of Pennsylvania, Philadelphia, PA, ³Pfizer Inc, Groton, CT, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵University of Oxford, Oxford, United Kingdom, ⁶Universidade Federal do Paraná, Curitiba, Brazil, ⁷Pfizer Canada, Montreal, QC, Canada, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Collegeville, PA, ¹⁰Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA).1 Rapid, sustained pain reduction is a priority for patients (pts) and physicians when choosing treatment.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.